Almutairy B K, Alshetaili A S, Ashour E A, Patil H, Tiwari R V, Alshehri S M, Repka M A
Pharmazie. 2016 Mar;71(3):128-33.
The present study aimed to develop a continuous single-step manufacturing platform to prepare a porous, low-density, and floating multi-particulate system (mini-tablet, 4 mm size). This process involves injecting inert, non-toxic pressurized CO₂gas (P-CO₂) in zone 4 of a 16-mm hot-melt extruder (HME) to continuously generate pores throughout the carrier matrix. Unlike conventional methods for preparing floating drug delivery systems, additional chemical excipients and additives are not needed in this approach to create minute openings on the surface of the matrices. The buoyancy efficiency of the prepared floating system (injection of P-CO₂) in terms of lag time (0 s) significantly improved (P < 0.05), compared to the formulation prepared by adding the excipient sodium bicarbonate (lag time 120 s). The main advantages of this novel manufacturing technique include: (i) no additional chemical excipients need to be incorporated in the formulation, (ii) few manufacturing steps are required, (iii) high buoyancy efficiency is attained, and (iv) the extrudate is free of toxic solvent residues. Floating mini-tablets containing acetaminophen (APAP) as a model drug within the matrix-forming carrier (Eudragit® RL PO) have been successfully processed via this combined technique (P-CO₂/HME). Desired controlled release profile of APAP from the polymer Eudragit® RL PO is attained in the optimized formulation, which remains buoyant on the surface of gastric fluids prior to gastric emptying time (average each 4 h).
本研究旨在开发一种连续单步制造平台,以制备一种多孔、低密度且漂浮的多颗粒系统(4毫米大小的迷你片)。该过程包括在16毫米热熔挤出机(HME)的4区注入惰性、无毒的加压二氧化碳气体(P-CO₂),以在整个载体基质中连续产生孔隙。与制备漂浮药物递送系统的传统方法不同,这种方法不需要额外的化学辅料和添加剂来在基质表面形成微小开口。与通过添加辅料碳酸氢钠制备的制剂(滞后时间120秒)相比,所制备的漂浮系统(注入P-CO₂)在滞后时间(0秒)方面的漂浮效率显著提高(P<0.05)。这种新型制造技术的主要优点包括:(i)制剂中无需加入额外的化学辅料,(ii)所需制造步骤少,(iii)获得高漂浮效率,(iv)挤出物无有毒溶剂残留。通过这种组合技术(P-CO₂/HME)已成功制备了在成膜载体(Eudragit® RL PO)中含有对乙酰氨基酚(APAP)作为模型药物的漂浮迷你片。在优化的制剂中,从聚合物Eudragit® RL PO获得了APAP所需的控释曲线,该制剂在胃排空时间(平均每4小时)之前在胃液表面保持漂浮。